Astellas Pharma Inc is a global pharmaceutical company developing therapies for the treatment of various diseases. Japanese Pharma major came into existence, as a result of merger of Fujisawa Pharmaceutical Co. and Yamanouchi Pharmaceutical Co. in Apr 2005.
- In Dec 2019, Astellas acquired Xyphos Biosciences for up to $665 Mn, to bolster the Astellas’ cancer immunotherapy pipeline with Xyphos’ advanced Cellular Control through Engineered Ligands (ACCEL) technology platform.
- In Dec 2018, Astellas acquired Potenza Therapeutics, Inc. in approx $ 400 Mn USD and make it, its wholly-owned subsidiary, establishing a fully owned clinical immune-oncology pipeline.
- In 2016, Astellas Pharma acquired Ganymed Pharmaceuticals for up to €1.282 billion ($1.4 billion), to expand its oncology portfolio. Ganymed’s pipeline include IMAB362 (now Zolbetuximab), a gastroesophageal cancer candidate designed to target the tight junction protein Claudin-18.2 (CLDN18.2), which is overexpressed in up to 80% of gastrointestinal adenocarcinomas (primary and metastasized) and 60% of pancreatic tumors, in addition to other solid cancers.
- In 2010, the company acquired OSI Pharmaceuticals, also operating as its wholly owned subsidiary, for $4.0 billion USD.
- In 2007, Astellas acquired Agensys Inc, currently operating as its wholly owned subsidiary, for $537 Mn USD.
Page 1 of 3
